2,3,3a,7a-tetrahydro-isoindol-1-one | 16327-30-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2,3,3a,7a-tetrahydro-isoindol-1-one
• 英文别名: 2,3,3a,7a-Tetrahydroisoindol-1-one
• CAS: 16327-30-3
• 化学式: C₈H₉NO
• 分子量: 135.166
• InChiKey: WRINNOJGJKBLPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
  申请人：Smith Nicholas D.

  公开号：US20130231333A1

  公开（公告）日：2013-09-05

  Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述了一些雌激素受体调节剂化合物。还描述了包括所述化合物的制药组合物和药物，以及使用这些雌激素受体调节剂，单独或与其他化合物结合，治疗与雌激素受体介导或依赖的疾病或症状的方法。
• Modulators of Cellular Adhesion
  申请人：SHEN Wang

  公开号：US20120035154A1

  公开（公告）日：2012-02-09

  The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R 1 -R 4 , n, p, A, B, D, E, L and AR 1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).

  本发明提供具有式（I）的化合物及其药学上可接受的衍生物，其中R1-R4、n、p、A、B、D、E、L和AR1通常在此处描述，并提供其制药组合物以及使用它们治疗由CD11/CD18细胞粘附分子家族介导的疾病的方法（例如LFA-1）。
• Modulators of cellular adhesion
  申请人：Shen Wang

  公开号：US20080176896A1

  公开（公告）日：2008-07-24

  The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R 1 -R 4 , n, p, A, B, D, E, L and AR 1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
• US7745460B2
  申请人：——

  公开号：US7745460B2

  公开（公告）日：2010-06-29